Cara Therapeutics, Inc. (CARA) Financials

CARA Assets vs Liabilities
DateAssetsLiabilities
Sept. 30, 2024 51.3 million 50.6 million
June 30, 2024 72.5 million 60.9 million
March 31, 2024 90.1 million 60.3 million
Dec. 31, 2023 125.8 million 68.8 million

CARA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2024 -14.0 million 1.5 million
June 30, 2024 -12.6 million 1.7 million
March 31, 2024 -31.3 million 3.3 million
Dec. 31, 2023 -19.4 million 3.6 million

CARA Net Income

No data available :(

CARA Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2024 42.0 million - 3.4 million
June 30, 2024 56.6 million 7.3 million 7.5 million
March 31, 2024 69.8 million 45.2 million 7.0 million
Dec. 31, 2023 101.2 million 43.2 million 6.1 million

CARA Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2024 54.8 million
June 30, 2024 54.7 million
March 31, 2024 54.6 million
Dec. 31, 2023 54.5 million

CARA Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2024 - 1.4 million 6.5 million -
June 30, 2024 210000 9.3 million 6.4 million -39000
March 31, 2024 836000 22.0 million 6.8 million -30000
Dec. 31, 2023 2.1 million 28.4 million 6.5 million -

CARA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2024 2.6 million -
June 30, 2024 991000 77000
March 31, 2024 2.1 million 662000
Dec. 31, 2023 3.0 million 690000

CARA Revenue by Segment
Graph available only for paid members. Upgrade to see it.

CARA

Price: $5.32

52 week price:
2.71
11.34

Earnings Per Share: -15.53 USD

P/E Ratio: -0.32

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 393100

Ebitda: -12.8 million

Market Capitalization: 22.6 million

Links: